Concerns over BMS and Celgene merger payout as FDA extends drug reviewBristol-Myers Squibb’s risky three-drug bet with former shareholders in Celgene is still on – but it could be Share XConcerns over BMS and Celgene merger payout as FDA extends drug reviewhttps://pharmaphorum.com/news/concerns-over-bms-and-celgene-merger-payout-as-fda-extends-drug-review/
